Results 21 to 30 of about 37,305 (235)

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis

Blood Advances, 2018
: Lenalidomide is associated with increased risk of thromboembolism (VTE) in patients with multiple myeloma. This risk has not previously been defined in B-cell non-Hodgkin lymphoma (NHL), for which lenalidomide is also an active agent.
Samuel Yamshon, Paul J. Christos, Michelle Demetres, Hoda Hammad, John P. Leonard, Jia Ruan   +5 more
doaj   +1 more source

Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Chinese Medical Journal, 2015
Background: Lenalidomide has emerged as an important treatment for patients with multiple myeloma (MM). However, its role in the management of MM is still controversial and requires further clarification.
Shu-Kai Qiao, Xiao-Nan Guo, Jin-Hai Ren, Han-Yun Ren   +3 more
doaj   +1 more source

Low Dose of Lenalidomide Enhances NK Cell Activity: Possible Implication as an Adjuvant [PDF]

Iranian Journal of Immunology, 2017
Background: Lenalidomide, a synthetic immunomodulatory drug, has a wide range of features including anti-angiogenic and anti-proliferative properties. To date, researchers have shown that lenalidomide is capable of ameliorating the immune system factors ...
Kiandokht Borhani, Taravat Bamdad, Tayebeh Hashempour   +2 more
doaj  

Long Term Therapy with Lenalidomide in a patient with POEMS Syndrome

European Journal of Case Reports in Internal Medicine, 2014
Lenalidomide is an effective therapy against malignant plasma cells and a potent agent against proinflammatory and proangiogenic cytokines. The use of lenalidomide in POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein with plasma ...
Benjamin Chu, Arwa Shana'ah, Craig C Hofmeister, Don M Benson, Yvonne A Efebera   +4 more
doaj   +1 more source

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs) [PDF]

, 2009
Thalidomide and lenalidomide are FDA approved for the treatment of multiple myeloma and, along with pomalidomide, are being investigated in various other cancers. Although these agents display immunomodulatory, anti-angiogenic and anti-apoptotic effects,
Galustian, C, J Y Henry, Liu, WM, Meyer, B, Bartlett, JB, A G Dalgleish, Henry, JY, Liu, W M, Henry, J Y, Bartlett, J B, Dalgleish, AG, B Meyer, W M Liu, J B Bartlett, Dalgleish, A G, C Galustian   +15 more
core   +1 more source

Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.

PLoS ONE, 2013
UnlabelledThis study assessed the immunomodulatory effects in previously treated KRAS-mutant metastatic colorectal cancer patients participating in a phase II multicenter, open-label clinical trial receiving lenalidomide alone or lenalidomide plus ...
Anita K Gandhi, Tao Shi, Mingyu Li, Ulf Jungnelius, Alfredo Romano, Josep Tabernero, Salvatore Siena, Peter H Schafer, Rajesh Chopra   +8 more
doaj   +1 more source

HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy

OncoImmunology, 2018
Recent studies suggest that CLL is an immunogenic disease, which might be effectively targeted by antigen-specific T-cell-based immunotherapy. However, CLL is associated with a profound immune defect, which might represent a critical limitation for ...
Annika Nelde, Daniel J. Kowalewski, Linus Backert, Heiko Schuster, Jan-Ole Werner, Reinhild Klein, Oliver Kohlbacher, Lothar Kanz, Helmut R. Salih, Hans-Georg Rammensee, Stefan Stevanović, Juliane S. Walz   +11 more
doaj   +1 more source

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

Haematologica, 2012
Background Although lenalidomide is very effective in the treatment of anemia of lower risk myelodysplastic syndromes with 5q deletion (del 5q), concerns have been raised over the fact that this drug could trigger progression to acute myeloid leukemia in
Lionel Adès, Fabien Le Bras, Marie Sebert, Charikleia Kelaidi, Thierry Lamy, François Dreyfus, Virginie Eclache, Jacques Delaunay, Didier Bouscary, Sorin Visanica, Pascal Turlure, Agnès Guerci Bresler, Marie-Paule Cabrol, Anne Banos, Michel Blanc, Norbert Vey, Alain Delmer, Eric Wattel, Sylvie Chevret, Pierre Fenaux   +19 more
doaj   +1 more source

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN). [PDF]

Am J Hematol
Our meta‐analysis showed significant improvement of PFS with lenalidomide, proteasome inhibitors, and CD38‐based therapies. A significant OS benefit was noted only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS.
Ludwig H, Terpos E, Gay F, van de Donk NWCJ, Bernhard S, Engelhardt M, Cook G, Schjesvold F, Einsele H, Jackson G, Pawlyn C, Mateos MV, Zweegman S, Schreder M, Beksaç M, Driessen C, Ocio EM, Popat R, Rasche L, Touzeau C, Musto P, Broijl A, Dimopoulos M, Hajek R, Boccadoro M, Sonneveld P.   +25 more
europepmc   +2 more sources

Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis

EBioMedicine, 2017
At our center, relapsed mantle cell lymphoma (MCL) can be treated with maintenance therapy composed of consecutive low-dose lenalidomide and short-term, high-dose dexamethasone (LD regimen), which achieves good responses (longer overall survival and ...
Jiexian Ma, Kefei Wu, Weiya Bai, Xiaoxian Cui, Yan Chen, Youhua Xie, Yanhui Xie   +6 more
doaj   +1 more source